Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

PURPOSE: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (...

Full description

Saved in:
Bibliographic Details
Published in:Int J Chron Obstruct Pulmon Dis
Main Authors: Miravitlles, Marc, Gáldiz, Juan B, Huerta, Alicia, Villacampa, Alba, Carcedo, David, Garcia-Rio, Francisco
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2016
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723026/
https://ncbi.nlm.nih.gov/pubmed/26848262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S94006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items